The information on this website is intended for healthcare
professionals only and is provided for the purpose of scientific exchange.
The website is not country specific and may therefore contain
information that is not applicable in your country, thus you may find
information concerning study drugs or therapeutic uses that have not
been approved by drug regulatory agencies. This website is not
intended to promote in any way, any use, either approved, or
unapproved, of a Novo Nordisk product or of any other product or serve
as basis for any treatment decision or action. Please always refer to
Summary of Product Characteristics (product label) as approved by
regulatory authorities in your country or contact Novo Nordisk for
Furthermore, the site is not intended to replace the advice of a
healthcare professional and should not be construed as providing
advice or making a recommendation. Only a physician can determine
whether a specific product is correct for a particular patient. Novo
Nordisk accepts no liability for the accuracy, completeness or use of
this information, and disclaims any liability to update the
information contained on this site.
By accessing this website you accept this legal notice and expressly
confirm your status as a healthcare professional.
ADA 2021 June 25 - 29
Once-Weekly Semaglutide 2.4 Mg Improved Glucose Metabolism And Prediabetes In Adults With Overweight/Obesity In The STEP 1 Trial
Leigh Perreault1; Melanie Davies2; Juan P Frias3; Peter Norkjaer Laursen4; Ildiko Lingvay5; Sriram Machineni6; Anette Varbo4; John PH Wilding7; Signe Olrik Rytter Wallenstein4; Carel W le Roux8;
1 Department of Medicine/Division of Endocrinology, Metabolism and Diabetes, University of Colorado Anschutz Medical Campus, Aurora, CO, USA; 2 Diabetes Research Centre, University of Leicester, Leicester, UK; 3 National Research Institute, Los Angeles, CA, USA; 4 Novo Nordisk A/S, Soborg, Denmark; 5 Departments of Internal Medicine/Endocrinology and Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas, TX, USA; 6 Division of Endocrinology and Metabolism/Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, USA; 7 Department of Cardiovascular and Metabolic Medicine, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK; 8 Diabetes Complications Research Centre Conway Institute University College, Dublin, Ireland;